Clinical features and outcome of lupus myocarditis in the Western Cape, South Africa

Lupus

Volumn 26, Issue 1, 2017, Pages 38-47

  Du Toit, R ^a   Herbst, P G ^a   Van Rensburg, A ^a   Du Plessis, L M ^a   Reuter, H ^a   Doubell, A F ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

echocardiography; ethnicity; lupus mortality; lupus nephritis; myocarditis; Systemic lupus erythematosus

Indexed keywords

ANTICOAGULANT AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DANAZOL; DIURETIC AGENT; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLATE MOFETIL; PHOSPHOLIPID ANTIBODY; PREDNISONE; RIBONUCLEOPROTEIN ANTIBODY; RITUXIMAB;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL FEATURE; CLINICAL OUTCOME; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS MYOCARDITIS; LUPUS VULGARIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYOCARDITIS; PLASMA EXCHANGE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SLEDAI; SOUTH AFRICA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; ACUTE DISEASE; ADOLESCENT; ANCESTRY GROUP; COMPLICATION; ETHNOLOGY; PROGNOSIS; STATISTICS AND NUMERICAL DATA; TIME FACTOR; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; CONTINENTAL POPULATION GROUPS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPENIA; MALE; MYOCARDITIS; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; SOUTH AFRICA; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 85006110344     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316651741     Document Type: Article

References (45)

1. Wijetunga M, Rockson S,. Myocarditis in systemic lupus erythematosus. Am J Med 2002; 113: 419-423.
2. Appenzeller S, Pineau C, Clarke A,. Acute lupus myocarditis: Clinical features and outcome. Lupus 2011; 20: 981-988.
3. Apte M, McGwin G, Vila LM, et al. Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort. Rheumatology 2007; 47: 362-367.
4. Alarcón GS, Friedman AW, Straaton KV, et al. Systemic lupus erythematosus in three ethnic groups: III A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus 1999; 8: 197-209.
5. Wadee S, Tikly M, Hopley M,. Causes and predictors of death in South Africans with systemic lupus erythematosus. Rheumatology 2007; 46: 1487-1491.
6. Tikly M, Burgin S, Mohanlal P, et al. Autoantibodies in black South Africans with systemic lupus erythematosus: Spectrum and clinical associations. Clin Rheumatol 1996; 15: 261-265.
7. Tikly M, Gould T, Wadee AA, et al. Clinical and serological correlates of antinucleosome antibodies in South Africans with systemic lupus erythematosus. Clin Rheumatol 2007; 26: 2121-2125.
8. Statistics South Africa statistical release P0302. Mid-year population estimates, 2013, http://www.statssa.gov.za/publications/P0302/P03022013.pdf (2013, accessed 26 November 2015).
9. Statistics South Africa. Census 2011, Census in brief, http://www.statssa.gov.za/census/census-2011/census-products/Census-2011-Census-in-brief. (2011, accessed 26 November 2015).
10. Quintana-Murci L, Harmant C, Quach H, et al. Strong maternal Khoisan contribution to the South African coloured population: A case of gender-biased admixture. Am J Hum Genet 2010; 86: 611-620.
11. Okpechi I, Swanepoel C, Duffield M, et al. Patterns of renal disease in Cape Town South Africa: A 10-year review of a single-centre renal biopsy database. Nephrol Dial Transplant 2011; 26: 1853-1861.
12. Okpechi IG, Ayodele OE, Jones ESW, et al. Outcome of patients with membranous lupus nephritis in Cape Town South Africa. Nephrol Dial Transplant 2012; 27: 3509-3515.
13. Bates WD, Halland A-M, Tribe RD, et al. Lupus nephritis. Part I. Histopathological classification, activity and chronicity scores. S Afr Med J 1991; 79: 256-259.
14. Naicker S,. Patterns of renal disease in South Africa. Nephrology 1998; 4 (Suppl. 2): S21-S24.
15. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
16. Ramsey-Goldman R, Isenberg DA,. Systemic lupus erythematosus measures: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Measure (SLEDAI), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index (SLICC/ACR-DI; SDI). Arthritis Rheum 2003; 49: S225-S233.
17. Lang R, Bierig M, Devereux R, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79-108.
18. British Society of Echocardiography Education Committee. Echocardiography: Guidelines for chamber quantification, http://www.bsecho.org/media/40506/chamber-final-2011-2-.pdf (2011, accessed 29 July 2015).
19. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis. Eur Heart J 2012; 33: 1750-1757.
20. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med 2005; 142: 953-962.
21. Zawadowski G, Klarich K, Moder K, et al. A contemporary case series of lupus myocarditis. Lupus 2012; 21: 1378-1384.
22. Williams RC, Harmon ME, Burlingame R, et al. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol 2005; 32: 454-461.
23. Zhang L, Zhu Y-L, Li M-T, et al. Lupus myocarditis: A case-control study from China. Chin Med J (Engl) 2015; 128: 2588-2594.
24. Bidani AK, Roberts JL, Schwartz MM, et al. Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med 1980; 69: 849-858.
25. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530.
26. Morgera T, Lenarda AD, Dreas L, et al. Electrocardiography of myocarditis revisited: Clinical and prognostic significance of electrocardiographic changes. Am Heart J 1992; 124: 455-467.
27. Smith SC, Ladenson JH, Mason JW, et al. Elevations of cardiac troponin I associated with myocarditis: Experimental and clinical correlates. Circulation 1997; 95: 163-168.
28. Sawalha AH, Harley JB,. Antinuclear autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 2004; 16: 534-540.
29. Borenstein DG, Fye B, Arnett FC, et al. The myocarditis of systemic lupus erythematosus. Ann Intern Med 1978; 89: 619-624.
30. Logar D, Kveder T, Rozman B, et al. Possible association between anti-Ro antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Ann Rheum Dis 1990; 49: 627-629.
31. Cervera R, Font J, Pare C, et al. Cardiac disease in systemic lupus erythematosus: Prospective study of 70 patients. Ann Rheum Dis 1992; 51: 156-159.
32. Nihoyannopoulos P, Gomez PM, Joshi J, et al. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 1990; 82: 369-375.
33. Chow LH, Radio SJ, Sears TD, et al. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol 1989; 14: 915-920.
34. Pinamonti B, Alberti E, Cigalotto C, et al. Echocardiographic findings in myocarditis. Am J Cardiol 1988; 62: 285-291.
35. Giunta A, Picillo U, Maione S, et al. Spectrum of cardiac involvement in systemic lupus erythematosus: Echocardiographic, echo-Doppler observations and immunological investigation. Acta Cardiol 1993; 2: 183-197.
36. Micheloud D, Calderon M, Caparrros M, et al. Intravenous immunoglobulin therapy in severe lupus myocarditis: Good outcome in three patients. Ann Rheum Dis 2007; 66: 986-987.
37. Barnado A, Kamen DL,. Myocarditis successfully treated with intravenous immunoglobulin in a patient with systemic lupus erythematous and myositis. Am J Med Sci 2014; 347: 256-257.
38. Suri V, Varma S, Joshi K, et al. Lupus myocarditis: Marked improvement in cardiac function after intravenous immunoglobulin therapy. Rheumatol Int 2010; 30: 1503-1505.
39. Ramos-Casals M, Soto M, Cuadrado M, et al. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009; 18: 767-776.
40. Petri M,. Measuring disease activity and severity in clinical trials and the clinic: Same or different? Arthritis Res Ther 2013; 15 (Suppl. 2): A4-A4.
41. Gottenberg J-E, Roux S, Assayag P, et al. Specific cardiomyopathy in lupus patients: Report of three cases. Joint Bone Spine 2004; 71: 66-69.
42. Panchal L, Divate S, Vaideeswar P, et al. Cardiovascular involvement in systemic lupus erythematosus: An autopsy study of 27 patients in India. J Postgrad Med 2006; 52: 5-10.
43. Huang B-T, Yao H-M, Huang H,. Left ventricular remodelling and dysfunction in systemic lupus erythematosus: A three-dimensional speckle tracking study. Echocardiography 2014; 31: 1085-1094.
44. Zhang Y, Corona-Villalobos CP, Kiani AN, et al. Myocardial T2 mapping by cardiovascular magnetic resonance reveals subclinical myocardial inflammation in patients with systemic lupus erythematosus. Int J Cardiovasc Imaging 2015; 31: 389-397.
45. Singh J, Woodard P, Dávila-Román V, et al. Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: A preliminary report. Lupus 2005; 14: 137-144.